Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. AUTL
AUTL logo

AUTL

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AUTL News

Autolus Therapeutics Reports Strong 2025 Earnings with AUCATZYL Launch Success

3d agoseekingalpha

AUCATZYL® 2025 Financial Results and Market Outlook

3d agoNewsfilter

Autolus Therapeutics Q4 Earnings Report Analysis

3d agoseekingalpha

Autolus Therapeutics Earnings Announcement Scheduled

4d agoseekingalpha

Precision Biologics Market Awakens to $71 Billion Opportunity

Feb 05 2026Globenewswire

Precision Biologics Market Awakens to $71 Billion Opportunity

Feb 05 2026Newsfilter

Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%

Jan 14 2026Benzinga

Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion

Jan 06 2026Newsfilter

Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab

Dec 29 2025Benzinga

DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion

Dec 29 2025Benzinga

BTIG Raises Praxis Precision Medicines Price Target to $843

Dec 29 2025Benzinga

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg Dose

Dec 19 2025PRnewswire

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

Dec 19 2025Newsfilter

Autolus Unveils New Phase I Results for Obe-cel in Challenging Lupus Cases

Dec 09 2025NASDAQ.COM

Autolus Presents CARLYSLE Trial Preliminary Data Showing Significant B-Cell Depletion

Dec 08 2025Globenewswire

Autolus Presents CARLYSLE Trial Preliminary Data Showing Significant B-Cell Depletion Improvement

Dec 08 2025Newsfilter